In oncology, dysregulated expression of BRCC36-containing complexes is closely linked to tumor initiation, progression, invasion, and metastasis in cancers such as breast cancer, hepatocellular carcinoma, and leukemia. This evidence concerns the gene BRCC3 and cancer.